Fecal Calprotectin Use in Inflammatory Bowel Disease and Beyond: A Mini-Review by Bashaar Alibrahim, Mohammed I Aljasser, Baljinder Salh

“…The present article summarizes the experience with this test used in inflammatory bowel disease, as well as a variety of gastrointestinal disorders.…”
Get full text

Fecal Microbiota Transplantation Improves the Quality of Life in Patients with Inflammatory Bowel Disease by Yao Wei, Weiming Zhu, Jianfeng Gong, Dong Guo, Lili Gu, Ning Li, Jieshou Li

“…Fecal microbiota transplantation improves quality of life significantly in patients with inflammatory bowel disease.…”
Get full text

Review of Russian Abstracts Accepted for United European Gastroenterology Week (2022) by A. A. Sheptulin

Subjects: “…inflammatory bowel diseases…”
Get full text

Assessment tools for transition readiness in adolescents with inflammatory bowel disease: A scoping review. by YaHui Zuo, Mei Li, JinJin Cao, JiaNan Wang, WenQian Cai, Lu Zhang, Meng Li

“…<h4>Background</h4>Assessing the level of transition readiness in adolescents with inflammatory bowel disease is crucial; however, standardized research tools are lacking. …”
Get full text

Fatty Acids of Erythrocyte Membranes and Blood Serum in Differential Diagnosis of Inflammatory Bowel Diseases by M. V. Kruchinina, I. O. Svetlova, M. F. Osipenko, N. V. Abaltusova, A. A. Gromov, M. V. Shashkov, A. S. Sokolova, I. N. Yakovina, A. V. Borisova

Subjects: “…inflammatory bowel diseases…”
Get full text

Evaluation of the Clinical Efficacy of Prednisolone in the Treatment of Inflammatory Bowel Diseases with Different Dosage Methods by O. P. Alekseeva, S. V. Krishtopenko, A. A. Alekseeva

“…In this study were included 86 patients aged from 18 to 65 years with moderate or severe active inflammatory bowel disease (61 — UC, 25 — CD). All patients were treated with prednisolone at an initial daily dose from 30 to 60 mg with a subsequent tapering of dose. …”
Get full text

Quality improvement exercises in Inflammatory Bowel Disease (IBD) services: A scoping review. by Katie Ridsdale, Kajal Khurana, Azizat Temidayo Taslim, Jessica K Robinson, Faith Solanke, Wei Shao Tung, Elena Sheldon, Daniel Hind, Alan J Lobo

“…<h4>Objective</h4>Quality Improvement initiatives aim to improve care in Inflammatory Bowel Disease (IBD). These address a range of aspects of care including adherence to published guidelines. …”
Get full text

Initial Development and Validation of a Transition Readiness Scale for Adolescents with Inflammatory Bowel Disease by Oded Hammerman, Areej Bayatra, Dan Turner, Arie Levine, Raanan Shamir, Amit Assa, Michael Wilschanski, Yaacov G. Bachner, Eran Israeli

Get full text

Prevalence of Self-Reported Spondyloarthritis Features in a Cohort of Patients with Inflammatory Bowel Disease by Carmen Stolwijk, Marieke Pierik, Robert Landewé, Ad Masclee, Astrid van Tubergen

“…BACKGROUND: Musculoskeletal symptoms belonging to the spectrum of ‘seronegative spondyloarthritis’ (SpA) are the most common extraintestinal manifestations in patients with inflammatory bowel disease (IBD) and may lead to important disease burden. …”
Get full text

Thyroid disorders and inflammatory bowel disease: an association present in adults but also in children and adolescents by Valeria Calcaterra, Valeria Calcaterra, Francesca Penagini, Virginia Rossi, Luisa Abbattista, Alice Bianchi, Massimiliano Turzi, Lucia Cococcioni, Gianvincenzo Zuccotti, Gianvincenzo Zuccotti

Subjects: Get full text

Risk Factors for Worsening of Bone Loss in Patients Newly Diagnosed with Inflammatory Bowel Disease by Yi Yin, Xiaofeng Lu, Zhun Li, Song Liu, Lihua Shao, Lei Cao, Rui-Qing Liu, Liang-Yu Huang, Zhen-Xing Zhu, Zhen Guo, Yi Li, Wei-Ming Zhu

“…Bone loss is common in patients with inflammatory bowel disease (IBD). The aim of the present study was to determine the prevalence of metabolic bone disease in patients newly diagnosed with IBD and to identify the risk factors for bone loss over time. …”
Get full text

CUZD1 and Anti-CUZD1 Antibodies as Markers of Cancer and Inflammatory Bowel Diseases by Christos Liaskos, Eirini I. Rigopoulou, Timoklia Orfanidou, Dimitrios P. Bogdanos, Christos N. Papandreou

“…CUZD1, the CUB, and zona pellucida-like domains-containing protein 1, is a newly identified antigen of pancreatic autoantibodies (PAB) giving a reticulogranular pattern in patients with inflammatory bowel diseases, and in particular Crohn’s disease. …”
Get full text

The Frequency of Clinic Visits Was Not Associated with Medication Adherence or Outcome in Children with Inflammatory Bowel Diseases by Cheryl Kluthe, Jenkin Tsui, Donald Spady, Matthew Carroll, Eytan Wine, Hien Quoc Huynh

“…Medication nonadherence is a challenge in pediatric patients with inflammatory bowel diseases (IBD). Poor adherence can result in disease flare-ups, disease complicationstherapy escalation, and the need for corticosteroids. …”
Get full text

Comment on “Biomarkers as Potential Treatment Targets in Inflammatory Bowel Disease: A Systematic Review” by Nicholas-Paul Delicata, Neville Azzopardi, Pierre Ellul

Get full text

Lupus-Like Syndrome Caused by 5-Aminosalicylic Acid in Patients with Inflammatory Bowel Disease by Andrew W Kirkpatrick, Arthur A Bookman, Flavio Habal

“…BACKGROUND: Although 5-aminosalicylic acid (5-ASA) preparations used to treat inflammatory bowel disease are reported to have fewer side effects than sulphasalazine, increased clinical use of these compounds has resulted in increased reports of significant side effects.…”
Get full text

Mesalazine-Induced Acute Pancreatitis in Inflammatory Bowel Disease Patients: A Systematic Review by Pan J, Li Z, Ye C, Zhang X, Yang Q, Zhang X, Zhou Y, Zhang J

“…Juan Pan,1,&ast; Zuyi Li,1,&ast; Chao Ye,2 Xiaojuan Zhang,1 Qiongliang Yang,1 Xu Zhang,1 Ya Zhou,3 Jianjun Zhang2 1Department of Pharmacy, Liuyang Hospital of Traditional Chinese Medicine, Changsha, Hunan, 410300, People’s Republic of China; 2Department of Pharmacy, Guangdong Provincial second Hospital of Traditional Chinese Medicine (Guangdong Provincial Engineering Technology Research Institute of Traditional Chinese Medicine), Guangzhou, Guangdong, 510095, People’s Republic of China; 3Department of Pharmacy, People’s Hospital of Ningxiang City Affiliated to Hunan University of Chinese Medicine, Changsha, Hunan, 410600, People’s Republic of China&ast;These authors contributed equally to this workCorrespondence: Chao Ye, Department of Pharmacy, Guangdong Provincial second Hospital of Traditional Chinese Medicine (Guangdong Provincial Engineering Technology Research Institute of Traditional Chinese Medicine), No. 60, Hengfu Road, Guangzhou, Guangdong, 510095, People’s Republic of China, Email yechao1234256@163.comObjective: Mesalazine is a widely used medication for treating mild to moderate inflammatory bowel disease (IBD). First identified as a potential cause of acute pancreatitis (AP) in 1989, the link between mesalazine and AP has primarily been established through case reports and a limited number of retrospective studies. …”
Get full text

Mesenchymal Stem Cell-derived Exosomes: Novel Therapeutic Approach for Inflammatory Bowel Diseases by Cheng-mei Tian, Mei-feng Yang, Hao-ming Xu, Min-zheng Zhu, Yuan Zhang, Jun Yao, Li-sheng Wang, Yu-jie Liang, De-feng Li

“…The anti-inflammatory and immunomodulatory activities of mesenchymal stem cell (MSC)-derived Exos (MSC-Exos) provide a rationale for novel cell-free therapies for inflammatory bowel disease (IBD). Growing evidence has shown that MSC-Exos can be a potential candidate for treating IBD. …”
Get full text

Intestinal inflammation in TNBS sensitized rats as a model of chronic inflammatory bowel disease by N. Selve, T. Wöhrmann

“…The applicability and relevance of this new model are discussed with respect to drug development and basic research of inflammatory bowel diseases.…”
Get full text

The Utility of Fecal Calprotectin in the Real-World Clinical Care of Patients with Inflammatory Bowel Disease by Esmail Abej, Wael El-Matary, Harminder Singh, Charles N. Bernstein

Get full text

Therapeutic application and potential mechanism of plant-derived extracellular vesicles in inflammatory bowel disease by Jinling Li, Ting Luo, Dou Wang, Yao Zhao, Yuanxiang Jin, Guiling Yang, Xin Zhang

Subjects: Get full text